A Communication-Priming Intervention to Improve Shared Decision-Making Between Older Adults With Advanced CKD and Clinicians
Launched by THE UNIVERSITY OF HONG KONG · Jan 27, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new approach called the "CKD Jumpstart- Tips" to help older adults with advanced chronic kidney disease (CKD) make better decisions about their treatment options. The goal is to improve communication between patients and their healthcare providers, making it easier for both sides to agree on the best treatment based on the patient’s preferences and values. Researchers believe that using this tool will lead to more shared decision-making, better communication, and ultimately a higher quality of life for patients.
To participate in this trial, you need to be an older adult diagnosed with advanced CKD Stage 4 or 5 and able to speak Chinese or English. You should also have a scheduled clinic visit to discuss treatment options with your doctor. If you are currently on dialysis, eligible for a kidney transplant, or have difficulty making decisions, you won't be able to participate. If you join the study, you can expect to engage in discussions about your treatment, fill out some questionnaires, and help researchers understand how to improve patient-clinician communication. This study aims to make a real difference in how treatment decisions are made for older adults with CKD.
Gender
ALL
Eligibility criteria
- Inclusion criteria for the two groups of participants (i.e. Clinicians and Patients):
- • 1. Clinicians
- • - Nephrology specialists or higher physician trainees who provide specialty care to older adults with advanced chronic kidney disease
- • 2. Patients
- • Diagnosis of advanced CKD Stage 4 or 5 (eGRF \<30 ml/min)
- • Chinese- or English-speaking
- • Identified as patient with whom their clinician plans to discuss advanced kidney disease treatment options in the upcoming clinic visit
- • Able to provide written informed consent and complete questionnaires
- • Can be contacted by phone
- Exclusion criteria for patients:
- • Patients will be excluded if they are eligible for kidney transplant, currently on dialysis, or lack decision-making capacity
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Jacqueline KY Yuen, Dr
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported